12479 results for

Refine Your Search

Manabu Fujisawa

Manabu Fujisawa

Dr. Manabu Fujisawa received M.D. from Kyushu University in Fukuoka, Japan. Motivated by the experience as a hematologist having treated many patient …

Catherine Diefenbach

Catherine Diefenbach

I am a translational lymphoma researcher and associate professor at the NYU Perlmutter Cancer Center (PCC). My research focuses on the relationship be…

The Role of the DNA Sensor AIM2 in B Cell Fate and Function After HCT

Altered B cell homeostasis plays a key role in the development of chronic (cGVHD) after hematopoietic stem cell transplantation (HCT). We hypothesize…

Fahmin Basher

Fahmin Basher

Fahmin Basher, MD, PhD completed her bachelor’s degrees in chemical engineering and biological sciences at the University of South Carolina. She then …

John DiPersio

John DiPersio

John F. DiPersio MD, PhD is the Golman Professor of Medicine and Director of The Center for Gene and Cellular Immunotherapy at the Washington Universi…

Targeting Epigenetics in Myeloid Malignancies

We have a highly collaborative team of investigators, whose goal is to develop novel therapeutic approaches to MDS and AML as well as to improve curre…

Reina Takeda

Reina Takeda

Reina Takeda, M.D., Ph. D., is a hematologist and currently a Research Fellow in Pediatric Oncology at Cancer Institute (DFCI). After receiving her M…

Development of BET protein bromodomain inhibitors for the treatment of patients with hematologic malignancies

In July , LLS began its partnership with Constellation to support three Phase clinical trials for blood cancer patients and the partnership led to t…

Yoke Seng Lee

Yoke Seng Lee

My scientific background involves the functional characterization of rare immune cells called dendritic cells in advanced melanoma patients. These cel…

Yoke Seng Lee

My scientific background involves the functional characterization of rare immune cells called dendritic cells in advanced melanoma patients. These cel…

A phase 2 study of AFM13, a bispecific cell engager targeting CD30 and CD16A, in combination with AB-101 (allogeneic natural killer cells) in patients with classical HL and CD30-positive PTCL

In August , LLS began its first European partnership with Affimed that supported two clinical trials for Hodgkin lymphoma (HL) patients. Expanding upo…

Patrizia Mondello

Patrizia Mondello

I am a focusing on the biology and therapeutic targeting of lymphoma. I trained in Medical Oncology in Italy. Given my interest in the molecular mec…

Jianguo Tao

Jianguo Tao

I am a trained clinical hematopathologist and who is well versed in both basic and translational studies in hematologic tumors, with a special intere…

Lawrence Boise

Lawrence Boise

Lawrence Boise, PhD is the R. Randall Rollins Chair of Oncology and Professor in the Department of Hematology and Medical Oncology in the Emory Univer…

Functional dissection of heterogeneity of responses to CAR T cells using Spatiotemporal Image-guided Genomic and Cellular Analysis (SaGA) in myeloma

Despite remarkable progress in the last years, multiple myeloma remains an incurable disease. In recent years, CAR T cell products that target BCMA …

Mark Murakami

Mark Murakami

Dr. Mark Murakami is a dedicated to advancing curative treatments for follicular lymphoma. Based in the Division of Hematologic Neoplasia at the Can…

Bing Carter

Bing Carter

Dr. Carter, a Professor in the Section of Molecular Hematology and Therapy, Department of Leukemia has + years of experience in molecular biology, bio…

Fenghuang Zhan

Fenghuang Zhan

Fenghuang (Frank) Zhan, MD & PhD, is a Professor of Medicine and the Research Director of Myeloma Center at University of Arkansas for Medical Science…

Nicola Vannini

Nicola Vannini

Nicola Vannini after his MSc degree in Biological Sciences obtained at the University of Parma, moved to La Jolla (CA) where he worked for two years a…

Jake Shortt

Jake Shortt

Professor Jake Shortt is a clinician scientist who is by Monash Health as Director of Clinical Haematology and by Monash University as the Head of Ha…

Exploiting escape from Y-inactivation as a synthetic dependency in MYC-driven lymphoma

As a lymphoma develops it expresses genes that are normally silenced to convey a survival advantage. When these genes are on the X or Y (sex chromosom…

Jake Shortt

Professor Jake Shortt is a clinician scientist who is by Monash Health as Director of Clinical Haematology and by Monash University as the Head of Ha…

Paul Beavis

Paul Beavis

I am an Assoc. Prof. and Group Leader at the Peter MacCallum Cancer Centre (Peter Mac; Melbourne, Australia).